Genmab Upbeat About Advancing Acasunlimab As BioNTech Exits

Genmab A/S's ability to drive compounds through late-stage trials on its own will be put to the test following the news that BioNTech SE has pulled out of a pact to further co-develop acasunlimab for lung cancer.

The Danish biotech is assuming sole responsibility to advance acasunlimab, a PD-L1 x 4-1BB bispecific antibody, after its Germany-headquartered partner opted not to participate in further development